• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Xilio Therapeutics, Inc. - Common Stock (NQ:XLO)

    9.220 +0.170 (+1.88%)
    Streaming Delayed Price Updated: 11:55 AM EDT, Aug 4, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Xilio Therapeutics, Inc. - Common Stock

    < Previous 1 2 3 Next >
    News headline image
    Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Xilio Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer
    From Xilio Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updates
    From Xilio Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Xilio Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2
    From Xilio Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Xilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D. to its Board of Directors
    From Xilio Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Xilio Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2025 Financial Results
    From Xilio Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Xilio Therapeutics to Present New Preclinical Data for its Masked T Cell Engager Program Targeting CLDN18.2 at the American Association for Cancer Research (AACR) Annual Meeting
    From Xilio Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Xilio Therapeutics Announces 1-for-14 Reverse Stock Split
    From Xilio Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Xilio Therapeutics to Present at the Leerink Partners Global Healthcare Conference
    From Xilio Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Xilio Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Xilio Therapeutics Announces Pricing of Underwritten Offering
    From Xilio Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Xilio Therapeutics Highlights Upcoming Milestones and Recent Corporate Updates
    From Xilio Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2025 Financial Results
    From Xilio Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting
    From Xilio Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Xilio Therapeutics Highlights Portfolio of Differentiated Masked Immunotherapies at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting
    From Xilio Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Xilio Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Xilio Therapeutics to Present Phase 2 Data for Vilastobart Highlighting Response Rate in Patients with MSS mCRC and High Plasma Tumor Mutational Burden as a Late-Breaking Presentation at SITC 40th Annual Meeting
    From Xilio Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting
    From Xilio Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Xilio Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Xilio Therapeutics Announces Initiation of Phase 2 Trial for Efarindodekin Alfa (XTX301), a Tumor-Activated IL-12, and Achievement of $17.5 Million Development Milestone Under Exclusive License Agreement with Gilead
    From Xilio Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2025 Financial Results
    From Xilio Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Catalyst Pharmaceuticals Appoints Daniel Curran, MD, to its Board of Directors
    From Catalyst Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Xilio Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Xilio Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors
    From Xilio Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Xilio Therapeutics Announces Closing of $50.0 Million Public Offering
    From Xilio Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Xilio Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Xilio Therapeutics Announces Pricing of $50.0 Million Public Offering
    From Xilio Therapeutics, Inc.
    Via GlobeNewswire
    < Previous 1 2 3 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.